Professor Sarnoff was quoted, saying the ruling was favorable for doctors and patients but left some uncertainty. He explained that the Supreme Court ruling "was not entirely clear on all issues related to genetic material, so Myriad will probably assert its other patents unless and until it is told that they, too, are invalid."